zalunfiban

Phase 3Small molecule

zalunfiban is one of 3 small molecule programs targeting ST-elevation Myocardial Infarction (STEMI). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ST-Elevation Myocardial Infarction (STEMI)Active, not recruiting

ST-Elevation Myocardial Infarction (STEMI)Phase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in ST-Elevation Myocardial Infarction (STEMI)

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Phase 2

1 2

zalunfiban

CCeleCor Therapeutics

Phase 3

1 3

Adenocard

Astellas

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unspecified1 trial

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

Active, not recruiting·CCeleCor Therapeutics·Phase 3·NCT04825743·2,463 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for zalunfiban. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zalunfiban compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zalunfiban. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CeleCor Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCeleCor Therapeutics

zalunfiban

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News